Who is sponsoring NCT07274059?

NCT07274059 is sponsored by Chengdu Ucello Biotechnology Co., Ltd..

What drugs are being tested in NCT07274059?

Interventions in NCT07274059: allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA.

What condition does NCT07274059 study?

NCT07274059 studies SLE - Systemic Lupus Erythematosus.

Is NCT07274059 still recruiting?

NCT07274059 is currently recruiting now. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT07274059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic UCB-derived CAR-T for SLE

Recruiting now EARLY_PHASE1 Last updated 10 December 2025

What this trial tests

EARLY_PHASE1 trial testing allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA in SLE - Systemic Lupus Erythematosus in 48 participants. Currently enrolling.

Timeline

26 March 2025

Primary endpoint
31 December 2035

31 December 2037

Quick facts

Lead sponsor	Chengdu Ucello Biotechnology Co., Ltd.
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	26 March 2025
Primary completion	31 December 2035
Estimated completion	31 December 2037
Sites	2 locations across China

Drugs / interventions tested

allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA — full drug profile →

Conditions studied

SLE - Systemic Lupus Erythematosus — all drugs for SLE - Systemic Lupus Erythematosus →

Sponsor

Chengdu Ucello Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with SLE - Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for SLE - Systemic Lupus Erythematosus

Currently open trials in the same condition.

NCT07315087 — CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases · Phase 1 · recruiting
NCT07193810 — A Study of CC312 for Relapsed/Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07177911 — Safety and Efficacy Study of CC312 for Moderate to Severe SLE · Phase 1 · recruiting
NCT06189157 — MB-CART19.1 in Refractory SLE · Phase 1, PHASE2 · recruiting

Other Chengdu Ucello Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT07266311 — CAR-T for Claudin18.2 Positive Solid Tumors · EARLY_PHASE1 · not yet recruiting
NCT07266337 — CD19/BCMA CAR-T for SLE · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07274059 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chengdu Ucello Biotechnology Co., Ltd.
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07274059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing